Press Release
-
Active Brown Adipose Tissue Protects Against “Pre-Prediabetes”
May 4, 2022
—
In a prospective study of young, lean adults, PET/CT imaging revealed that higher levels of active brown adipose tissue (also known as “brown fat”) are more prevalent in individuals who exhibit very early indications of metabolic disorders. The research was published ahead of print in The Journal of Nuclear Medicine.
-
JNM Publishes Joint Guide for the Establishment of Theranostics Centers
Apr 29, 2022
—
SNMMI, the European Association of Nuclear Medicine, and the International Atomic Energy Agency have created a new guide for the creation of dedicated theranostics centers.
-
Novel Deep Learning Method Provides Early and Accurate Differential Diagnosis for Parkinsonian Diseases
Apr 21, 2022
—
A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published in JNM.
-
New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes
Apr 12, 2022
—
SNMMI and ASNC have released a new “80 Hour Radionuclide Authorized User Training Course” for nuclear medicine physicians, which will fulfill the 80 hours of classroom training required by the NRC and Agreement States for physicians to become Authorized Users.
-
SNMMI Releases Statement on CMS Final Decision for Alzheimer’s Disease Coverage
Apr 8, 2022
—
CMS has announced its final decision on coverage of monoclonal antibodies to treat Alzheimer’s disease. It includes no additional coverage for beta amyloid PET scans, which will continue to be limited to one per patient per lifetime.
-
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients
Apr 7, 2022
—
A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre-treated metastatic castration-resistant prostate cancer. The research was published in the April issue of JNM.
-
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment
Mar 23, 2022
—
SNMMI applauds the FDA's approval of a new, game-changing nuclear medicine treatment for metastatic prostate cancer shown to reduce risk of death by 38% and risk of progression by 60% in mCRPC patients.
-
Molecular Imaging Uncovers Effects of COVID-19 on the Brain
Mar 15, 2022
—
A significant number of COVID-19 neurological complications—such as fatigue, headache, and cognitive impairment—are ultimately reversible, according to new research in The Journal of Nuclear Medicine.
-
SNMMI Designates First Radiopharmaceutical Therapy Centers of Excellence
Mar 10, 2022
—
SNMMI has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.
-
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients
Mar 9, 2022
—
A novel prostate cancer treatment—Ac-225 PSMA-617 radioligand therapy—has been shown to increase the progression free survival and overall survival of metastatic castration-resistant prostate cancer patients, according to research published by JNM.
-
SNMMI Launches New Quality Systems Personnel Training Program
Jan 31, 2022
—
SNMMI has launched the Quality Systems Personnel Training Program (QSPTP) to educate, train, and develop individuals with a pharmacy or chemistry background in the production and release of clinical radiopharmaceuticals.
-
PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence
Jan 20, 2022
—
Research published in the January issue of JNM has confirmed the accuracy of the European Association of Urology risk classification system that groups prostate cancer patients based on their risk of recurrence.
-
SNMMI Reacts to CMS Coverage Decision on New Alzheimer’s Therapy
Jan 12, 2022
—
On January 11, CMS announced that it proposes to cover FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under CED in CMS-approved randomized controlled trials. SNMMI reacts.
-
PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack
Jan 11, 2022
—
When assessed together in an AI model, coronary F-18 NaF uptake on PET and quantitative coronary plaque characteristics on CT angiography were found to provide risk prediction superior to that of clinical data alone.
-
JNM Publishes Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
Jan 7, 2022
—
SNMMI and peer medical groups have issued AUC for PSMA PET imaging. Published in the January issue of JNM, the criteria are the product of an international multidisciplinary panel of expert healthcare providers.
-
Senate Passes Protecting Medicare and American Farmers from Sequester Cuts Act
Dec 10, 2021
—
Last night, SNMMI and more than 300 medical societies rejoiced when the Senate passed the Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610).
-
Novel Radionuclide Therapy Proven Safe and Effective to Treat Neuroendocrine Neoplasms
Nov 19, 2021
—
A new type of PRRT has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients, according to research published in JNM.
-
SNMMI Adopts Family Leave Statement
Nov 12, 2021
—
SNMMI’s Women in Nuclear Medicine Committee, Nuclear Medicine Program Directors Committee, and Diversity, Equity and Inclusion Task Force collaborated to create an SNMMI Family Leave Statement, which was adopted by the SNMMI Board of Directors on November 1, 2021.
-
Molecular Imaging Suggests Long-COVID Symptoms May Be Caused by Fatigue, Not Regional Brain Dysfunction
Oct 29, 2021
—
Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than pathological changes in the brain, according to a study published ahead-of-print in JNM.
-
SNMMI 2021-2023 Wagner-Torizuka Fellowship Recipient Announced
Oct 15, 2021
—
SNMMI is pleased to announce the recipient of the 2021-2023 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. Applications are available for 2022-2024 fellowships.
-
PSMA PET Imaging More Accurate Than CT in Detecting Hepatocellular Carcinoma
Sep 30, 2021
—
PSMA PET/CT is more accurate than conventional CT in the detection of hepatocellular carcinoma metastases and was associated with a change of management for nearly half of patients, according to research published in the September issue of The Journal of Nuclear Medicine.
-
Newly Approved PET Imaging Agent Solves Clinical Dilemmas in Breast Cancer Patients
Sep 29, 2021
—
A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise, according to research published in the September issue of The Journal of Nuclear Medicine.
-
New Radionuclide Therapy Identified for HER2-Positive Breast Cancer Patients
Sep 28, 2021
—
A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine.
-
Topical Molecular Imaging Tracer Enables Real-Time Detection of Cervical Cancer
Jul 27, 2021
—
With the help of a topical fluorescent imaging agent, cervical cancer can be identified by physicians with a hand-held microscope, according to research published in the July issue of JNM.
-
Novel Imaging Agent Identifies Biomarker for Iron-Targeted Cancer Therapies
Jul 22, 2021
—
A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients.
-
Total-Body PET Imaging Exceeds Industry Standards
Jul 7, 2021
—
A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality, according to research published in The Journal of Nuclear Medicine.
-
Molecular Imaging Improves Staging and Treatment of Pancreatic Ductal Adenocarcinomas
Jul 5, 2021
—
For patients with pancreatic ductal adenocarcinomas, molecular imaging can improve staging and clinical management of the disease, according to research published in JNM.
-
Journal of Nuclear Medicine Impact Factor Surges More than 27%
Jul 1, 2021
—
The Journal of Nuclear Medicine has again achieved the highest impact factor ever in its history, now ranking third among all medical imaging journals worldwide, according to new data just released in the 2020 Journal Citation Reports.
-
SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President-Elect of the Technologist Section During 2021 Annual Meeting
Jun 15, 2021
—
Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, has been elected as the 2021-22 president-elect for the SNMMI-TS.
-
SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President of the Technologist Section During 2021 Annual Meeting
Jun 15, 2021
—
Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2021-22 president for the SNMMI-TS.
-
PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions
Jun 15, 2021
—
A phase III clinical trial has validated the effectiveness of the PSMA-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. This study was presented at the SNMMI 2021 Annual Meeting.
-
SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients
Jun 15, 2021
—
The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET), according to research presented at the SNMMI 2021 Annual Meeting. The detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame has been selected as SNMMI’s 2021 Image of the Year.
-
Novel Radiotracer Shows Promise to Predict Abdominal Aortic Aneurysm Rupture
Jun 15, 2021
—
A new PET radiotracer can detect abdominal aortic aneurysms and potentially predict when they will rupture, according to research presented at the SNMMI 2021 Annual Meeting.
-
SNMMI Elects Helen Nadel, MD, FRCPC, as Vice President-Elect at 2021 Annual Meeting
Jun 14, 2021
—
Helen Nadel, MD, FRCPC, has been named as SNMMI vice president-elect. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.
-
SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President-Elect at 2021 Annual Meeting
Jun 14, 2021
—
Munir Ghesani, MD, FACNM, FACR, has been named as SNMMI president-elect. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.
-
Society of Nuclear Medicine and Molecular Imaging Announces 2021 Fellows
Jun 14, 2021
—
SNMMI recognized 17 new SNMMI Fellows on Monday, June 14, during a plenary session at the society’s 2021 Annual Meeting, held virtually June 11-15.
-
Steven M. Larson, MD, Receives SNMMI 2021 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jun 14, 2021
—
Steven M. Larson, MD, has been named the 2021 recipient of the prestigious Paul C. Aebersold Award. The award was announced by the SNMMI during its 2021 Annual Meeting.
-
SNMMI Elects Richard L. Wahl, MD, as President During 2021 Annual Meeting
Jun 14, 2021
—
Richard L. Wahl, MD, has been elected 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.
-
New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge
Jun 14, 2021
—
A novel PET radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed. The research was presented at the SNMMI 2021 Annual Meeting.
-
Lipophilic Statin Use Linked to Increased Risk of Dementia
Jun 14, 2021
—
In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the SNMMI 2021 Annual Meeting, PET scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer’s disease.
-
New Theranostic Approach Combines Radiopharmaceuticals and Nanoparticles to Kill Cancer Cells
Jun 14, 2021
—
Researchers have successfully developed a novel cancer treatment approach that utilizes Cerenkov radiation energy to target and destroy cancer cells more effectively, according to new research presented at SNMMI’s 2021 Virtual Annual Meeting.
-
Novel Radiopharmaceutical Tracks “Master Switch” Protein Responsible for Cancer Growth
Jun 14, 2021
—
A protein that is critical in cancer cell metabolism has been imaged for the first time with a newly developed radiopharmaceutical, 18F-DASA-23, according to research presented at the SNMMI 2021 Annual Meeting.
-
Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events
Jun 13, 2021
—
Deep learning can predict major adverse cardiac events more accurately than current standard imaging protocols, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
-
Thomas J. Ruth, PhD, FRSC, FSRS, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award
Jun 13, 2021
—
Thomas J. Ruth, PhD, FRSC, FSRS, a scientist known for his contributions to nuclear medicine and nuclear chemistry, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
-
New Super-Resolution Technique Allows for More Detailed Brain Imaging
Jun 13, 2021
—
A new imaging technique termed "super-resolution" has the potential to detect neurological disorders—such as Alzheimer’s disease—at their earliest stages, enabling physicians to diagnose and treat patients more quickly.
-
PET Radiotracer Effective for Detection and Assessment of Lung Fibrosis
Jun 13, 2021
—
PET using a Ga-68–labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the SNMMI 2021 Annual Meeting.
-
Promising Ovarian Cancer Treatment Proves Effective and Efficient
Jun 12, 2021
—
Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.
-
With Advent of New Treatments, PET Imaging Adds Valuable Information to Brain Metastasis Monitoring
May 3, 2021
—
For patients with brain metastases, amino acid PET can provide valuable information about the effectiveness of state-of-the-art treatments.
-
New Radiotracer Safe and Effective for Imaging Early Rheumatoid Arthritis
Apr 15, 2021
—
New research shows that a novel PET tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.
-
New Treatment Proves More Effective and Less Toxic for Neuroendocrine Tumor Patients
Mar 19, 2021
—
A new treatment for late-stage neuroendocrine tumors has been found to be more effective and have fewer side effects than the current standard of care, according to research published in JNM.
-
Immuno-PET Can Give Physicians Early Insight into Tumor Response to Targeted Therapy
Mar 12, 2021
—
Immuno-PET imaging can provide early insight into a tumor’s response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.
-
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment
Feb 16, 2021
—
Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy, according to research published in the February issue of JNM.
-
Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model
Feb 6, 2021
—
A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of JNM.
-
Expanded PET Imaging Time Window Adds Convenience and Flexibility for Neuroendocrine Tumor Patients
Jan 20, 2021
—
The imaging time window of 64Cu-DOTATATE positron emission tomography/computed tomography (PET/CT) for patients with neuroendocrine neoplasms can be expanded from 1 hour to 3 hours post-injection, according to new research published in JNM.
-
Potential Jurors Favor Use of Artificial Intelligence in Precision Medicine
Jan 11, 2021
—
Physicians who follow artificial intelligence advice may be considered less liable for medical malpractice than is commonly thought, according to a new study published in JNM.
-
New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study
Dec 15, 2020
—
A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival, according to new research published in JNM.
-
PET Imaging Tracer Proves Effective for Diagnosing and Managing Rare CNS B-Cell Lymphoma
Dec 9, 2020
—
PET imaging with Ga-68-pentixafor is an effective diagnostic tool for central nervous system B-cell lymphoma, according to a proof-of-concept study published in the December issue of JNM.
-
The Journal of Nuclear Medicine Celebrates 60 Years of Research
Dec 9, 2020
—
The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.
-
FDA Announces First-Ever Approval of PSMA PET for Prostate Cancer Imaging
Dec 2, 2020
—
The FDA has approved ga-68 PSMA-11 for PET imaging of PSMA–positive lesions in men with prostate cancer. It is the first approval for a PSMA PET drug in the United States.
-
Multi-Center, Multi-Tracer PET Studies Harmonized to Detect Neuroinflammation in ALS
Dec 1, 2020
—
A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease.
-
Novel Therapy Approach for Hyperinsulinemic Hypoglycemia
Nov 6, 2020
—
A new method to treat hyperinsulinemic hypoglycemia has proved highly selective in targeting lesions and effective in slowing tumor growth, according to research published in the November issue of JNM.
-
Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
Oct 7, 2020
—
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research featured in the October issue of JNM.
-
Cerenkov Luminescence Imaging Accurately Identifies Surgical Margin Status During Radical Prostatectomy
Oct 6, 2020
—
A new intraoperative imaging technique, Cerenkov luminescence imaging, can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of JNM.
-
PET/MRI Improves Lesion Detection, Reduces Radiation Exposure
Sep 17, 2020
—
A study of more than 1,000 oncological examinations has demonstrated that PET/MRI facilitates cancer staging as well as PET/CT and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step.
-
SNMMI 2020-2022 Wagner-Torizuka Fellowship Recipients Announced
Sep 8, 2020
—
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2020-2022 SNMMI Wagner-Torizuka Fellowship.
-
Updated Statement: COVID-19 and Ventilation/Perfusion (V/Q) Lung Studies
Sep 3, 2020
—
SNMMI has released an updated statement on COVID-19 and ventilation/perfusion (V/Q) lung studies.
-
Virtual Patient Education Day Event Draws 600+ Viewers
Aug 28, 2020
—
SNMMI and its Patient Advocacy Advisory Board (PAAB) held the Society’s annual Patient Education Day this year as a series of three virtual sessions, reaching the highest number of patients in the event’s nine-year history.
-
New Approach for Calculating Radiation Dosimetry Allows for Individualized Therapy
Aug 10, 2020
—
Researchers from Peter MacCallum Cancer Centre have developed a simplified dosimetry method that could enhance personalization of cancer therapy based on a single posttreatment scan.
-
A Virtual Celebration of Life for Sam Gambhir, MD, PhD to take place on Friday, August 14, 2020
Aug 8, 2020
—
A Virtual Celebration of Life will take place on Friday, August 14, 2020 to honor molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, who passed away on Saturday, July 18, from cancer.
-
New Multiple Myeloma Therapy Shows Promise in Preclinical Study
Aug 6, 2020
—
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to research published in JNM.
-
Patient, Healthcare Provider Groups Join Together to Promote a #ReturnToCare
Aug 4, 2020
—
More than a dozen patient advocacy organizations and medical societies have formed a coalition to promote public health by encouraging patients to seek necessary screenings, vaccinations, scans, and treatments that have been put off as a result of concerns about COVID-19.
-
Genomic Signature Explains FDG-Avidity of PSMA-Suppressed Prostate Tumors
Jul 22, 2020
—
Scientists from the University of Windsor have investigated why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).
-
Molecular Imaging Pioneer Sam Gambhir Passes Away
Jul 19, 2020
—
Molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer.
-
SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President-Elect of the Technologist Section During 2020 Annual Meeting
Jul 14, 2020
—
Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2020-21 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section.
-
SNMMI Announces Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, as President of Technologist Section during 2020 Annual Meeting
Jul 14, 2020
—
Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, has been named 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section.
-
SNMMI Image of the Year: Super-Agers Show Resistance to Tau and Amyloid Accumulation, Maintain High Cognitive Function
Jul 14, 2020
—
Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting.
-
SNMMI Elects Richard L. Wahl, MD, as President-Elect During 2020 Annual Meeting
Jul 13, 2020
—
Richard L. Wahl, MD, has been elected 2020-21 president-elect of the Society of Nuclear Medicine and Molecular Imaging.
-
SNMMI Elects Alan B. Packard, PhD, as President During 2020 Annual Meeting
Jul 13, 2020
—
Alan Packard, PhD, has been elected 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging.
-
Society of Nuclear Medicine and Molecular Imaging Announces 2020 Fellows
Jul 13, 2020
—
The Society of Nuclear Medicine and Molecular Imaging recognized 10 new SNMMI Fellows on Monday, July 13, during a plenary session at the society’s 2020 Annual Meeting.
-
SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as Vice President-Elect During 2020 Annual Meeting
Jul 13, 2020
—
Munir Ghesani, MD, FACNM, FACR, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.
-
Novel Bone Imaging Approach Provides Insights into the Progression of Knee Osteoarthritis
Jul 12, 2020
—
A new approach to functional bone imaging has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis.
-
Total-Body Dynamic PET Successfully Detects Metastatic Cancer; First Patient Results Reported
Jul 12, 2020
—
Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
-
In Recurrent Prostate Cancer, PSMA PET/CT Changes Management in Two-Thirds of Cases
Jul 12, 2020
—
New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients.
-
Molecular Imaging Identifies Link between Heart and Kidney Inflammation after Heart Attack
Jul 12, 2020
—
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack.
-
Carolyn J. Anderson, PhD, Receives SNMMI 2020 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jul 12, 2020
—
Carolyn J. Anderson, PhD, has been named the 2020 recipient of the prestigious Paul C. Aebersold Award. Anderson is a professor in the departments of medicine, radiology, bioengineering, chemistry, and pharmacology and chemical biology at the University of Pittsburgh in Pennsylvania.
-
Stephen L. Bacharach, PhD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award
Jul 12, 2020
—
Stephen L. Bacharach, PhD, a physicist known for his research in cardiac and PET oncology imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
-
New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors
Jul 12, 2020
—
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.
-
New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management
Jul 11, 2020
—
A new molecular imaging approach utilizing 18F-FDG positron emission tomography (PET) and magnetic resonance imaging can precisely identify the location of pain generators in chronic pain sufferers, often precipitating a new management plan for patients.
-
Total-Body PET/CT Captures Full Picture of Systemic Inflammatory Arthritis
Jul 11, 2020
—
For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneously across all joints and organ systems, using the high-sensitivity, high-resolution uEXPLORER total-body positron emission tomography/computed tomography scanner
-
Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies
Jul 11, 2020
—
Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate cancer that improves the effectiveness of immunotherapies.
-
Novel Radiotracer Measures Synaptic Activity After Stroke
Jul 11, 2020
—
A new radiotracer, 18F-SynVesT-2, can directly assess synaptic density changes in the brain, providing an objective and quantitative measure of disease progression after stroke.
-
New Theranostic Agents Demonstrate Efficacy in Treatment of Prostate Cancer in Preclinical Studies
Jul 11, 2020
—
Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies.
-
Journal of Nuclear Medicine Impact Factor Jumps More than Seven Percent
Jun 29, 2020
—
The Journal of Nuclear Medicine has achieved the highest impact factor ever in its 6o-year history, ranking fourth among all medical journals worldwide, according to new data just released in the 2019 Journal Citation Reports published by Clarivate Analytics.
-
Novel Radiotracer Proves Advantageous for Imaging Neuroendocrine Tumor Patients with Liver-Dominant Disease
Jun 24, 2020
—
For neuroendocrine cancer patients with liver metastases, a new radiopharmaceutical has shown excellent imaging performance in tumor detection, staging and restaging, providing important information to guide treatment.
-
Nuclear Medicine and COVID-19: New Content from The Journal of Nuclear Medicine
Jun 9, 2020
—
Five new COVID-related articles and commentaries are published in the June issue of The Journal of Nuclear Medicine (JNM).
-
New Research Reveals Potentially Treatable Genetic Mutations in Patients Resistant to PSMA-Targeting Therapy
May 20, 2020
—
Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine.
-
Molecular Imaging Provides Insight into Therapeutic Outcomes for Neuroendocrine Tumor Patients Days after Treatment
May 13, 2020
—
Nuclear medicine can identify early response to Lu-177 DOTATATE treatment in neuroendocrine tumor patients, according to a new study in the May issue of The Journal of Nuclear Medicine.
-
Novel Radiotracer Meets Gold Standard for Imaging Prostate Cancer, Offers Benefits over Established Imaging Agent
May 8, 2020
—
The novel radiopharmaceutical F-18-PSMA-1007 is effective for detecting malignant prostate cancer lesions and readily available, according to research published in the April issue of The Journal of Nuclear Medicine.
-
Technologists Answer Questions about COVID-19
May 5, 2020
—
The COVID-19 crisis has forced nuclear medicine departments to cancel appointments, change procedures and protocols and adapt rapidly to significant changes. To provide guidance to the community, SNMMI-TS interviewed eight nuclear medicine technologists from around the country.
-
Announcement: SNMMI Annual Meeting
Apr 30, 2020
—
SNMMI President Vasken Dilsizian, MD, shares an important message unveiling the re-imagined SNMMI 2020 Annual Meeting—Virtual Edition.
-
Travel Considerations Specified for Lu-177-DOTATATE Radiation Therapy Patients
Apr 24, 2020
—
A team of researchers and patient advocates has addressed the challenges related to traveling after receiving Lu-177-DOTATATE radiation therapy in a study published in The Journal of Nuclear Medicine.
-
New Radiotracer Offers Opportunities for Earlier Intervention after Heart Attack
Dec 18, 2019
—
A new radiotracer can effectively image fibroblast activation after a heart attack, identifying a window of time during which cardiac fibrosis can be prevented and the disease course altered. The study is featured in The Journal of Nuclear Medicine.
-
Finding a Non-invasive Way to Predict Effectiveness of Cancer Therapy
Dec 12, 2019
—
Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumors, allowing for personalized, precision treatment. The study is featured in the December issue of The Journal of Nuclear Medicine.
-
Novel Theranostic Reagent Could Enhance Detection and Therapy of Prostate Cancer
Nov 26, 2019
—
A novel nuclear medicine radiotracer could help identify the extent of metastatic prostate cancer and select patients for therapy. The study is featured in The Journal of Nuclear Medicine.
-
New Technique Could Optimize PSMA-Targeted Prostate Cancer Therapy
Nov 13, 2019
—
Researchers have discovered a new way to optimize results in treating patients with prostate cancer tumors while minimizing negative side effects. The study is featured in the November issue of The Journal of Nuclear Medicine.
-
Therapy for Neuroendocrine Tumors May Be Improved by Patient-Specific Dosimetry
Oct 28, 2019
—
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment, according to new research published in The Journal of Nuclear Medicine.
-
Optoacoustic Imaging Shows Potential for Noninvasive Diagnostics for Thyroid Disorders
Oct 22, 2019
—
A new noninvasive imaging technique can provide novel biomarker information for initial evaluation and differential diagnosis of thyroid disorders.
-
PET Offers More Precise Screening Method to Select Candidates for Radionuclide Therapy
Sep 24, 2019
—
PET scanning can offer more precise selection of patients for neuroendocrine tumor therapy, allowing some patients to qualify who would otherwise have been ineligible, according to an article featured in The Journal of Nuclear Medicine.
-
Bipartisan Group Moves to Expand Access to Diagnostic Radiopharmaceuticals
Jul 17, 2019
—
On July 16, a bipartisan group introduced the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (HR 3772). The bill would expand patient access to highly targeted, precision diagnostic radiopharmaceuticals that evaluate conditions such as Alzheimer’s disease, Parkinson’s disease, and some cancers—allowing patients to get the right treatment faster and saving taxpayers money.
-
Influence of The Journal of Nuclear Medicine Jumps 25 Percent
Jun 27, 2019
—
The Journal of Nuclear Medicine again ranks among the top five medical imaging journals in the world. JNM continues to lead among nuclear medicine journals, with the highest impact factor (7.354), the highest immediacy index, the highest number of citations, the highest 5-year impact factor, the highest number of citable articles, and the highest influence score.
-
Molecular Imaging Suggests Smokers May Have Impaired Neuroimmune Function
Jun 25, 2019
—
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.
-
Ultrasmall Nanoclusters and Carbon Quantum Dots Show Promise for Treating Acute Kidney Injury
Jun 25, 2019
—
Two research studies offer hope for effective treatment and prevention on acute kidney injury.
-
New Combination Therapy Established as Safe and Effective for Prostate Cancer
Jun 25, 2019
—
A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects.
-
SNMMI Image of the Year: Novel Radiotracer Detects 28 Cancer Types, Paving the Way for Development of New Therapies
Jun 25, 2019
—
Each year, the SNMMI chooses an image that best exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. This year the honor goes to a team of researchers at University Hospital Heidelberg, Germany. Showcasing the efficacy of the FAPI radiotracer, the image demonstrates the uptake of the FAPI in 12 epidemiological tumor entities, including high uptake values in lung, breast, prostate, esophageal and pancreatic cancer.
-
Society of Nuclear Medicine and Molecular Imaging Announces 2019 Fellows
Jun 25, 2019
—
The Society of Nuclear Medicine and Molecular Imaging recognized 13 new SNMMI Fellows on Monday, June 24, during the Monday plenary session at the society’s 2019 Annual Meeting, held June 22-25 in Anaheim, California.
-
Radionuclide Therapy Effective in High-Grade Neuroendocrine Neoplasms
Jun 25, 2019
—
Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at SNMMI's 2019 Annual Meeting.
-
SNMMI Elects Richard L. Wahl, MD, as Vice President-Elect During 2019 Annual Meeting
Jun 24, 2019
—
Richard L. Wahl, MD, has been elected as 2019-20 vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Wahl is the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, director of the university’s Mallinckrodt Institute of Radiology and a professor of radiation oncology.
-
SNMMI Announces Mark H. Crosthwaite, MEd, CNMT, PET, NMTCB(S), FSNMMI-TS, as President of Technologist Section During 2019 Annual Meeting
Jun 24, 2019
—
Mark H. Crosthwaite, MEd, CNMT, PET, NMTCB(S), FSNMMI-TS, associate professor and program director of the baccalaureate nuclear medicine technology program, Department of Radiation Sciences, at Virginia Commonwealth University, Richmond, Virginia, has been named 2019-2020 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).
-
SNMMI Elects Vasken Dilsizian, MD, as President During 2019 Annual Meeting
Jun 24, 2019
—
Vasken Dilsizian, MD, professor of radiology and medicine at the University of Maryland School of Medicine and chief of the Division of Nuclear Medicine at the University of Maryland Medical Center in Baltimore, Maryland, has assumed office as 2019-20 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
-
SNMMI Elects Alan B. Packard, PhD, as President-Elect During 2019 Annual Meeting
Jun 24, 2019
—
Alan Packard, PhD, has been elected as 2019-20 president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Packard is associate professor of radiology at Harvard Medical School, director of radiopharmaceutical research and a senior research associate in nuclear medicine at Boston Children's Hospital, and research associate in nuclear medicine at Brigham and Women’s Hospital in Boston, Massachusetts.
-
Wearable Technology to Personalize Lu-177-DOTATATE Therapy for NETs
Jun 24, 2019
—
Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin-receptor-2 positive neuroendocrine tumors (NETs).
-
Nuclear Medicine PSMA-Targeted Study Offers New Options for Cancer Theranostics Worldwide
Jun 24, 2019
—
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) describes a new class of radiopharmaceuticals—radiohybrids—that offer a fresh perspective on cancer imaging and radioligand therapy (theranostics). In addition, the technology encompasses a highly innovative and efficient isotopic labeling method to facilitate broad application.
-
SNMMI Announces Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, as President-Elect of Technologist Section During 2019 Annual Meeting
Jun 24, 2019
—
Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, has been named 2019-2020 president-elect of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). Buehner is a health physicist specialist at Rush University Medical Center in Chicago, Illinois.
-
Earlier Diagnosis and Treatment Assessment of Tuberculosis Achieved with PET/CT
Jun 24, 2019
—
Research presented at SNMMI's 2019 Annual Meeting shows that molecular imaging with 18F-FDG PET/CT can evaluate tuberculosis at the molecular level, effectively identifying diseased areas and guiding treatment for patients.
-
Marcelo F. Di Carli, MD, Receives the SNMMI 2019 Georg Charles de Hevesy Nuclear Pioneer Award
Jun 23, 2019
—
Marcelo F. Di Carli, MD, was presented the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine at the SNMMI 2019 Annual Meeting, in Anaheim, California.
-
Jason S. Lewis, PhD, Receives SNMMI 2019 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jun 23, 2019
—
Jason S. Lewis, PhD, was presented the prestigious Paul C. Aebersold Award during the SNMMI 2019 Annual Meeting, June 22-25 in Anaheim, California.
-
Interim Scan during Prostate Cancer Therapy Helps Guide Treatment
Jun 23, 2019
—
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient’s treatment. The research was presented at the SNMMI 2019 Annual Meeting.
-
PET/CT Detects Cardiovascular Disease Risk Factors in Obstructive Sleep Apnea Patients
Jun 23, 2019
—
Research presented at SNMMI’s 2019 Annual Meeting draws a strong link between severe obstructive sleep apnea and impaired coronary flow reserve, which is an early sign of the heart disease atherosclerosis.
-
Novel Noninvasive Molecular Imaging for Monitoring Rheumatoid Arthritis
Jun 23, 2019
—
A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity. The study was presented at the SNMMI 2019 Annual Meeting.
-
Early Biomarker Found for Degenerative Neurologic Disease
Jun 22, 2019
—
Researchers have discovered a novel radioligand that can effectively differentiate progressive supranuclear palsy from similar brain disorders, allowing for earlier and more reliable diagnosis of the disease.
-
Immuno-PET Precisely Diagnoses IBD Inflammation without Invasive Procedures
Jun 17, 2019
—
Inflammation in inflammatory bowel disease can be quickly and precisely diagnosed using a new type of nuclear medicine scan. In addition, immuno-PET has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases. The research is featured in the June issue of The Journal of Nuclear Medicine.
-
New Radiotracer Can Identify Nearly 30 Types of Cancer
Jun 7, 2019
—
A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors. Using 68Ga-FAPI PET/CT, researchers were able to image the tumors with very high uptake and image contrast, paving the way for new applications in tumor characterization, staging and therapy. The research is featured in the June issue of The Journal of Nuclear Medicine.
-
Coronary Artery Disease Diagnosis Improved by Deep Learning Analysis of SPECT MPI
May 27, 2019
—
A multicenter international study has demonstrated that diagnosis of obstructive coronary artery disease can be improved through deep learning analysis of SPECT myocardial perfusion imaging. The research is featured in the May issue of The Journal of Nuclear Medicine.